Valuation: Inotiv, Inc.

Market Cap 387K 341K 322K 292K 549K 37.17M 552K 3.86M 1.49M 18.97M 1.45M 1.42M 60.96M P/E 2024
-0.41x
P/E 2025 -0.69x
Enterprise Value 438M 385M 364M 330M 620M 42.04B 624M 4.36B 1.68B 21.45B 1.64B 1.61B 68.93B EV / Sales 2024
0.95x
EV / Sales 2025 0.95x
Free-Float
93.37%
Yield 2024 *
-
Yield 2025 -
1 day-26.00%
3 months-7.50%
6 months-95.89%
Current year-98.03%
Current year 0.01
Extreme 0.007
0.65
1 year 0.01
Extreme 0.007
1.62
3 years 0.01
Extreme 0.007
11.42
5 years 0.01
Extreme 0.007
60.66
10 years 0.01
Extreme 0.007
60.66
Manager TitleAgeSince
Chief Executive Officer 67 12/01/2019
Director of Finance/CFO 61 06/03/2020
Chief Operating Officer 60 15/02/2021
Date Insider Type Main position Quantity % Market Cap. Importance
19/07/26 Others

Chief Executive Officer

-1,361,215 3.9017%
19/07/26 Others

Director

-729,626 2.0913%
19/07/26 Others

Chief Financial Officer

-139,616 0.4002%
Change 5-day change 1-year change 3-year change Capi.($)
-26.00%-.--%-99.20%-99.64% 387K
+2.64%+7.07%+11.87%+38.40% 47.97B
+0.22%+1.71%+50.91%+34.00% 44.5B
-1.58%+5.65%+359.34%+598.06% 43.93B
+1.70%+4.61%+12.56%+90.97% 41.03B
+0.51%-0.61%+5.18%+46.87% 29.85B
-0.48%+0.59%+23.98%+148.36% 17.27B
+0.08%+9.30%+8.41% - 15.34B
+1.76%+2.98%+29.13%+45.78% 15.3B
+1.97%-2.82% - - 14.82B
Average -1.98%-1.62%+44.69%+112.85% 27B
Weighted average by Cap. +0.68%+2.97%+79.47%+158.52%

Financials

2024 2025
Net sales 491M 432M 408M 370M 695M 47.11B 699M 4.89B 1.89B 24.04B 1.84B 1.8B 77.24B 513M 451M 427M 387M 727M 49.25B 731M 5.11B 1.97B 25.13B 1.93B 1.88B 80.75B
Net income -108M -95.38M -90.19M -81.8M -154M -10.41B -155M -1.08B -417M -5.31B -407M -398M -17.07B -68.62M -60.36M -57.07M -51.77M -97.22M -6.59B -97.78M -683M -264M -3.36B -258M -252M -10.8B
Net Debt 424M 373M 352M 320M 600M 40.67B 604M 4.22B 1.63B 20.75B 1.59B 1.56B 66.69B 438M 385M 364M 330M 620M 42B 623M 4.36B 1.68B 21.43B 1.64B 1.61B 68.87B
Logo Inotiv, Inc.
Inotiv, Inc. is a contract research company engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through DSA segment, it supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through RMS segment, it offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.
Employees
1,996
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. NOTV Stock